www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Allergy immunotherapy
    • Healthcare professionals
      • Reweal
      • Webinars
    • Pipeline
    • Clinical trials
    • Clinical data sharing
  • Our company
    • Newsroom
      • Stories
    • Privacy
    • Global presence
    • Organisation
    • History
    • Owners
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Board of Management
      • Board of Directors
      • Annual general meeting
      • Annual general meeting (DK)
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
      • ADR Programme
    • Contact IR
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar

« Back

Annual General Meeting in ALK-Abelló A/S held on 23 March 2023

March 23, 2023

PDF Version

ALK (ALKB:DC / OMX: ALK B / AKBLF): ALK-Abelló A/S held its Annual General Meeting on 23 March 2023.

The Annual General Meeting transacted the following business:

  • Adoption of the annual report 2022 and discharge of the Board of Directors and Board of Management
  • No declaration of ordinary dividend in accordance with the approved annual report for 2022
  • Adoption of the remuneration report for 2022
  • Adoption of the remuneration to the Board of Directors for the present year
  • Re-election of Anders Hedegaard as the Chair of the Board of Directors
  • Re-election of Lene Skole as the Vice Chair of the Board of Directors
  • Re-election of Gitte Aabo, Lars Holmqvist, Bertil Lindmark and Alan Main as well as new election of Jesper Høiland to the Board of Directors
  • Re-appointment of PwC Statsautoriseret Revisionspartnerselskab as the company’s auditor
  • Adoption of the following proposals from the Board of Directors:

            (a)   Renewed authority to the Board of Directors to purchase treasury shares

            (b)   Removal of Article 4.3 in the Articles of Association (the Company’s keeper of the shareholders' register)

            (c)   Update of the remuneration policy

            (d)   Authorisation to the chair of the meeting

ALK-Abelló A/S

        

For further information please contact:

Anders Hedegaard, Chair, tel. +45 4574 7576

About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,700 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment

  • FM_07_23UK_23032023
  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved